Crizanlizumab in adult patients with sickle cell disease: a retrospective German analysis
IntroductionThe marketing authorization for crizanlizumab (Adakveo®), indicated for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell patients (pts) aged ≥16, was revoked by the European Medicines Agency (EMA) as the STAND study did not demonstrate a significant difference betw...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2024-05-01
|
| Edice: | Frontiers in Hematology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/frhem.2024.1374181/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|